Credit Suisse AG Has $1.98 Million Position in Genomic Health, Inc. (NASDAQ:GHDX)

Credit Suisse AG boosted its stake in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 7.8% during the first quarter, Holdings Channel reports. The firm owned 62,764 shares of the medical research company’s stock after buying an additional 4,567 shares during the period. Credit Suisse AG’s holdings in Genomic Health were worth $1,977,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Columbia Wanger Asset Management LLC boosted its stake in shares of Genomic Health by 26.1% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,607,649 shares of the medical research company’s stock valued at $50,625,000 after buying an additional 332,311 shares during the period. Vanguard Group Inc. boosted its stake in shares of Genomic Health by 8.8% in the first quarter. Vanguard Group Inc. now owns 1,564,170 shares of the medical research company’s stock valued at $49,256,000 after buying an additional 126,807 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Genomic Health by 27.1% in the first quarter. Renaissance Technologies LLC now owns 733,200 shares of the medical research company’s stock valued at $23,088,000 after buying an additional 156,500 shares during the period. Loomis Sayles & Co. L P boosted its stake in shares of Genomic Health by 10.0% in the first quarter. Loomis Sayles & Co. L P now owns 584,515 shares of the medical research company’s stock valued at $18,406,000 after buying an additional 53,344 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Genomic Health by 8.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 482,675 shares of the medical research company’s stock valued at $15,200,000 after buying an additional 38,199 shares during the period. 89.53% of the stock is currently owned by hedge funds and other institutional investors.

Genomic Health, Inc. (NASDAQ GHDX) traded down 0.85% during mid-day trading on Thursday, reaching $30.26. 7,453 shares of the company’s stock were exchanged. The company’s 50 day moving average price is $32.41 and its 200-day moving average price is $31.12. The company’s market capitalization is $1.05 billion. Genomic Health, Inc. has a 52 week low of $25.66 and a 52 week high of $33.97.

Genomic Health (NASDAQ:GHDX) last released its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. The business had revenue of $85.50 million for the quarter, compared to analysts’ expectations of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.18) earnings per share. On average, equities research analysts expect that Genomic Health, Inc. will post $0.01 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Credit Suisse AG Has $1.98 Million Position in Genomic Health, Inc. (NASDAQ:GHDX)” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/2800318/credit-suisse-ag-has-1-98-million-position-in-genomic-health-inc-nasdaqghdx.html.

GHDX has been the topic of several analyst reports. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 18th. BidaskClub cut shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $31.00 target price on shares of Genomic Health in a report on Thursday, August 3rd. Raymond James Financial, Inc. reaffirmed a “market perform” rating on shares of Genomic Health in a report on Wednesday, May 3rd. They noted that the move was a valuation call. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a report on Monday, June 12th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $32.43.

In other news, Director Fred E. Cohen sold 8,250 shares of the stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $30.68, for a total transaction of $253,110.00. Following the completion of the transaction, the director now directly owns 74,145 shares in the company, valued at approximately $2,274,768.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Phillip G. Febbo sold 3,174 shares of the stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $33.57, for a total value of $106,551.18. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 75,642 shares of company stock valued at $2,342,466. Company insiders own 46.20% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.